Gabriella Miller Kids First Research Act 2.0

S 652/HR 2630: Safe Step Act- implementing safe guards around step therapy (fail first) programs in ERISA regulated plan S 1375/HR 830: HELP Copays Act- copay accumulator programs Addressing Pharmacy Benefit Managers S 127: Pharmacy Benefit Manager Transparency Act of 2023- prevents unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs S 79: Interagency Patent Coordination and Improvement Act of 2023- establishes an interagency taskforce between the United States Patent and Trademark Office and the FDA S 2243: Palliative Care and Hospice Education and Training Act (PCHETA)- promote education and research in palliative care and hospice Palliative care S 2213: Comprehensive Cancer Survivorship Act- cancer survivorship S 2039: Cancer Drug Parity Act of 2023- oral parity for cancer drugs HR 3633: PREVENT HPV Cancers Act of 2023 S 1624/HR 3391: Gabriella Miller Kids First Research Act 2.0- pediatric cancer research Addressing healthcare workforce shortages Increasing diversity in clinical trials Mitigating drug shortages and increasing supply chain resiliency and future pandemic preparedness, including bolstering the strategic national stockpile S 1961: Pharmaceutical Supply Chain Risk Assessment Act of 2023- require an interagency risk assessment of the pharmaceutical supply chain to identify and mitigate health and national security risks HR 3810: Drug Origin Transparency Act of 2023 - Require drug manufacturers to report to the Food and Drug Administration (FDA) quarterly the supplier's location and drug ingredients HR 3793: Ensuring Access to Lifesaving Drugs Act of 2023 - require manufacturers of life-saving drugs to submit data and information to assess the stability of the drugs and determine their longest supported expiration date, and for other purposes. S 2364: MAPS ACT - A bill to map the United States pharmaceutical supply chain S 2510: RAPID Reserve Act - establish reserves of both Active Pharmaceutical Ingredients (APIs) and finished drug products to be held as vendor-managed inventory and used when needed to prevent supply disruptions HR 5526: Seniors' Access to Critical Medications Act of 2023 - make permanent a waiver issued by the Centers for Medicare and Medicaid Services (CMS) that allowed for Medicare patients to receive critical medications by mail or allow for caregivers and family members to obtain medications for them. HR 6301: Cancer Drug Parity Act of 2023 - To amend the Employee Retirement Income Security Act of 1974 to require a group health plan (or health insurance coverage offered in connection with such a plan) to provide for cost-sharing for oral anticancer drugs on terms no less favorable than the cost-sharing provided for anticancer medications administered by a health care provider. HR 6963: To direct the Secretary of Health and Human Services to enter into agreements with drug manufacturers to establish reserve supplies of covered pediatric cancer drugs, and for other purposes - establish reserve supplies of covered pediatric cancer drugs, and for other purposes. HR 6992: Mapping America's Pharmaceutical Supply Act- require the Department of Health and Human Services to update its essential medicines list and create a database to help predict vulnerabilities in the U.S. pharmaceutical supply chain. S 3458: Seniors' Access to Critical Medications Act of 2023 - clarify the application of the in-office ancillary services exception to the physician self-referral prohibition for drugs furnished under the Medicare program. HR 8404/S 4330: ROCR Value Based Program Act of 2024 - To amend title XVIII of the Social Security Act to create a Radiation Oncology Case Rate Value Based Payment Program exempt from budget neutrality adjustment requirements, and to amend section 1128A of title XI of the Social Security Act to create a new statutory exception for the provision of free or discounted transportation for radiation oncology patients to receive radiation therapy services. HR 3633: Prevent HPV Cancers ACt of 2023 - To amend the Public Health Service Act to provide for a public awareness campaign with respect to human papillomavirus, and for other purposes. HR 3008: Drug Shortage Prevention Act of 2023 - To amend the Federal Food, Drug, and Cosmetic Act to provide for notification by manufacturers of critical essential medicines of increased demand of such drugs, and for other purposes. S 5368/HR 10239: End Drug Shortages Act - To amend the Federal Food, Drug, and Cosmetic Act to expand drug shortage notification practices to include surges in demand for a drug, and for other purposes.

Client expense: $90,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Childhood Cancer STAR Act (P.L. 115-180) Childhood Cancer STAR Reauthorization Act (P.L. 117-350) Fiscal Year 2024, Labor, Health, and Human Services Appropriation Fiscal Year 2024 Defense Appropriations H.R. 3391/S. 1624, the Gabriella Miller Kids First Research Act 2.0 H.R. 3663, the PREVENT HPV Cancers Act H.R. 4363/S. 2213, the Comprehensive Cancer Survivorship Act H.R. 4758/S. 2372, the Accelerating Kids' Access to Care Act

Client expense: Not reported · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Office of Science & Technology Policy (OSTP), SENATE

Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including Gabriella Miller Kids First Research Act 2.0 (HR 3391, S 1624); Accelerating Kids Access to Care Act(HR 3089, S 1544); Innovation in Pediatric Drugs Act of 2023 (HR 6664)

Client expense: $56,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including Gabriella Miller Kids First Research Act 2.0 (HR 3391, S 1624); Accelerating Kids Access to Care Act(HR 3089, S 1544); Innovation in Pediatric Drugs Act of 2023 (HR 6664)

Client expense: $119,942 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including Gabriella Miller Kids First Research Act 2.0 (HR 3391, S 1624); Accelerating Kids Access to Care Act(HR 3089, S 1544); Innovation in Pediatric Drugs Act of 2023 (HR 6664)

Client expense: $46,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 3991 / S 1624, the Gabriella Miller Kids First Act; Implementation of the Childhood Cancer STAR Reauthorization Act (enacted in 2022);

Client expense: $160,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE

HR 1692 / S 8, the Health Care Affordability Act; HR 2630 / S 652, the Safe Step Act; HR 3433 / S 2897, the Give Kids a Chance Act; HR 3503 / S 1701, The NIH Clinical Trial Diversity Act; HR 3991 / S 1624, the Gabriella Miller Kids First Act; HR 4363 / S 2213, Comprehensive Cancer Survivorship Act; HR 6003 / S 3103, the Medical Debt Relief Act; HR 6301 / S. 2039, The Cancer Drug Parity Act; HR 7383 / S 1214, the RARE Act; HR 8311 / S 4289, Medical Debt Cancellation Act; HR 824, the Telehealth Benefit Expansion for Workers Act; HR 1773, the Consumer Protection for Medical Debt Collections Act; HR 2813, Self-Insurance Protection Act; HR 2868, the Association Health Plans; HR 2880, the Protecting Patients Against PBM Abuses Act; HR 3799, CHOICE Arrangement Act; HR 3800, the Chronic Disease Flexible Coverage Act; HR 5609, the Advancing Health Savings Act; HR 5688, the Bipartisan HSA Improvement Act; HR 5687, the HSA Modernization Act; HR 6664, the Innovation in Pediatric Drugs Act; HR 6963, the Pediatric Cancer Drug Supply Chain Act; HR 7384, the Creating Hope Reauthorization Act; HR 8261, Preserving Telehealth, Hospital, and Ambulance Access Act; HR 8412, the Clinical Trial Modernization Act; HR 8574, the 340B ACCESS Act; HR 9129, Patient Debt Relief Act; S 113, the Prescription Pricing for the People Act; S 127, the Pharmacy Benefit Manager Transparency Act; S 1339, the Pharmacy Benefit Manager Reform Act; S 1542, the DRUG Act; S 1967 the Patients Before Middlemen Act; S 2243, the Palliative Care and Hospice Education and Training Act; S 2483, the Strengthening Consumer Protections and Medical Debt Transparency Act; S 2973, the Modernizing and Ensuring PBM Accountability Act; S 3167, Multiple Employer Welfare Arrangement (MEWA) Act; HR 9774 / S 5194, the Health Care Affordability Act; Legislation to protect insurance purchasers interacting with insurance brokers; Implementation of the No Surprises Act; Federal rulemaking related to Short-term Limited Duration Insurance (STLDI) plans; Efforts to extend and make permanent the current enhanced Advance Premium Tax Credits; Insurance appeals and denials; Federal rulemaking related to Association Health Plans; Consumer protections related to consumers who will lose insurance due to the end of certain federal Medicaid maintenance-of-effort requirements; FDA draft guidance related to dose optimization studies in clinical trials

Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including Gabriella Miller Kids First Research Act 2.0 (HR 3391, S 1624); Accelerating Kids Access to Care Act(HR 3089, S 1544); Innovation in Pediatric Drugs Act of 2023 (HR 6664)

Client expense: $50,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S 652/HR 2630: Safe Step Act- implementing safe guards around step therapy (fail first) programs in ERISA regulated plan S 1375/HR 830: HELP Copays Act- copay accumulator programs Addressing Pharmacy Benefit Managers S 127: Pharmacy Benefit Manager Transparency Act of 2023- prevents unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs S 79: Interagency Patent Coordination and Improvement Act of 2023- establishes an interagency taskforce between the United States Patent and Trademark Office and the FDA S 2243: Palliative Care and Hospice Education and Training Act (PCHETA)- promote education and research in palliative care and hospice Palliative care S 2213: Comprehensive Cancer Survivorship Act- cancer survivorship S 2039: Cancer Drug Parity Act of 2023- oral parity for cancer drugs HR 3633: PREVENT HPV Cancers Act of 2023 S 1624/HR 3391: Gabriella Miller Kids First Research Act 2.0- pediatric cancer research Addressing healthcare workforce shortages Increasing diversity in clinical trials Mitigating drug shortages and increasing supply chain resiliency and future pandemic preparedness, including bolstering the strategic national stockpile S 1961: Pharmaceutical Supply Chain Risk Assessment Act of 2023- require an interagency risk assessment of the pharmaceutical supply chain to identify and mitigate health and national security risks HR 3810: Drug Origin Transparency Act of 2023 - Require drug manufacturers to report to the Food and Drug Administration (FDA) quarterly the supplier's location and drug ingredients HR 3793: Ensuring Access to Lifesaving Drugs Act of 2023 - require manufacturers of life-saving drugs to submit data and information to assess the stability of the drugs and determine their longest supported expiration date, and for other purposes. S 2364: MAPS ACT - A bill to map the United States pharmaceutical supply chain S 2510: RAPID Reserve Act - establish reserves of both Active Pharmaceutical Ingredients (APIs) and finished drug products to be held as vendor-managed inventory and used when needed to prevent supply disruptions HR 5526: Seniors' Access to Critical Medications Act of 2023 - make permanent a waiver issued by the Centers for Medicare and Medicaid Services (CMS) that allowed for Medicare patients to receive critical medications by mail or allow for caregivers and family members to obtain medications for them. HR 6301: Cancer Drug Parity Act of 2023 - To amend the Employee Retirement Income Security Act of 1974 to require a group health plan (or health insurance coverage offered in connection with such a plan) to provide for cost-sharing for oral anticancer drugs on terms no less favorable than the cost-sharing provided for anticancer medications administered by a health care provider. HR 6963: To direct the Secretary of Health and Human Services to enter into agreements with drug manufacturers to establish reserve supplies of covered pediatric cancer drugs, and for other purposes - establish reserve supplies of covered pediatric cancer drugs, and for other purposes. HR 6992: Mapping America's Pharmaceutical Supply Act- require the Department of Health and Human Services to update its essential medicines list and create a database to help predict vulnerabilities in the U.S. pharmaceutical supply chain. S 3458: Seniors' Access to Critical Medications Act of 2023 - clarify the application of the in-office ancillary services exception to the physician self-referral prohibition for drugs furnished under the Medicare program. HR 8404/S 4330: ROCR Value Based Program Act of 2024 - To amend title XVIII of the Social Security Act to create a Radiation Oncology Case Rate Value Based Payment Program exempt from budget neutrality adjustment requirements, and to amend section 1128A of title XI of the Social Security Act to create a new statutory exception for the provision of free or discounted transportation for radiation oncology patients to receive radiation therapy services.

Childhood Cancer STAR Act (P.L. 115-180) Childhood Cancer STAR Reauthorization Act (P.L. 117-350) Fiscal Year 2024, Labor, Health, and Human Services Appropriation Fiscal Year 2024 Defense Appropriations H.R. 3391/S. 1624, the Gabriella Miller Kids First Research Act 2.0 H.R. 3663, the PREVENT HPV Cancers Act H.R. 4363/S. 2213, the Comprehensive Cancer Survivorship Act H.R. 4758/S. 2372, the Accelerating Kids' Access to Care Act

Client expense: Not reported · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Office of Science & Technology Policy (OSTP), SENATE

S 652/HR 2630: Safe Step Act- implementing safe guards around step therapy (fail first) programs in ERISA regulated plan S 1375/HR 830: HELP Copays Act- copay accumulator programs Addressing Pharmacy Benefit Managers S 127: Pharmacy Benefit Manager Transparency Act of 2023- prevents unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs S 79: Interagency Patent Coordination and Improvement Act of 2023- establishes an interagency taskforce between the United States Patent and Trademark Office and the FDA S 2243: Palliative Care and Hospice Education and Training Act (PCHETA)- promote education and research in palliative care and hospice Palliative care S 2213: Comprehensive Cancer Survivorship Act- cancer survivorship S 2039: Cancer Drug Parity Act of 2023- oral parity for cancer drugs HR 3633: PREVENT HPV Cancers Act of 2023 S 1624/HR 3391: Gabriella Miller Kids First Research Act 2.0- pediatric cancer research Addressing healthcare workforce shortages Increasing diversity in clinical trials Mitigating drug shortages and increasing supply chain resiliency and future pandemic preparedness, including bolstering the strategic national stockpile S 1961: Pharmaceutical Supply Chain Risk Assessment Act of 2023- require an interagency risk assessment of the pharmaceutical supply chain to identify and mitigate health and national security risks HR 3810: Drug Origin Transparency Act of 2023 - Require drug manufacturers to report to the Food and Drug Administration (FDA) quarterly the supplier's location and drug ingredients HR 3793: Ensuring Access to Lifesaving Drugs Act of 2023 - require manufacturers of life-saving drugs to submit data and information to assess the stability of the drugs and determine their longest supported expiration date, and for other purposes. S 2364: MAPS ACT - A bill to map the United States pharmaceutical supply chain S 2510: RAPID Reserve Act - establish reserves of both Active Pharmaceutical Ingredients (APIs) and finished drug products to be held as vendor-managed inventory and used when needed to prevent supply disruptions HR 5526: Seniors' Access to Critical Medications Act of 2023 - make permanent a waiver issued by the Centers for Medicare and Medicaid Services (CMS) that allowed for Medicare patients to receive critical medications by mail or allow for caregivers and family members to obtain medications for them. HR 6301: Cancer Drug Parity Act of 2023 - To amend the Employee Retirement Income Security Act of 1974 to require a group health plan (or health insurance coverage offered in connection with such a plan) to provide for cost-sharing for oral anticancer drugs on terms no less favorable than the cost-sharing provided for anticancer medications administered by a health care provider. HR 6963: To direct the Secretary of Health and Human Services to enter into agreements with drug manufacturers to establish reserve supplies of covered pediatric cancer drugs, and for other purposes - establish reserve supplies of covered pediatric cancer drugs, and for other purposes. HR 6992: Mapping America's Pharmaceutical Supply Act- require the Department of Health and Human Services to update its essential medicines list and create a database to help predict vulnerabilities in the U.S. pharmaceutical supply chain. S 3458 Seniors' Access to Critical Medications Act of 2023 - clarify the application of the in-office ancillary services exception to the physician self-referral prohibition for drugs furnished under the Medicare program.

HR 3991 / S 1624, the Gabriella Miller Kids First Act; Implementation of the Childhood Cancer STAR Act (enacted in 2022);

Client expense: $570,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE

HR 1692 / S 8, the Health Care Affordability Act; HR 2630 / S 652, the Safe Step Act; HR 3433 / S 2897, the Give Kids a Chance Act; HR 3503 / S 1701, The NIH Clinical Trial Diversity Act; HR 3991 / S 1624, the Gabriella Miller Kids First Act; HR 4363 / S 2213, Comprehensive Cancer Survivorship Act; HR 6003 / S 3103, the Medical Debt Relief Act; HR 6301 / S. 2039, The Cancer Drug Parity Act; HR 7383 / S 1214, the RARE Act; HR 824, the Telehealth Benefit Expansion for Workers Act; HR 1773, the Consumer Protection for Medical Debt Collections Act; HR 2813, Self-Insurance Protection Act; HR 2868, the Association Health Plans; HR 2880, the Protecting Patients Against PBM Abuses Act; HR 3799, CHOICE Arrangement Act; HR 3800, the Chronic Disease Flexible Coverage Act; HR 5609, the Advancing Health Savings Act; HR 5688, the Bipartisan HSA Improvement Act; HR 5687, the HSA Modernization Act; HR 6664, the Innovation in Pediatric Drugs Act; HR 6963, the Pediatric Cancer Drug Supply Chain Act; HR 7384, the Creating Hope Reauthorization Act; S 113, the Prescription Pricing for the People Act; S 127, the Pharmacy Benefit Manager Transparency Act; S 1339, the Pharmacy Benefit Manager Reform Act; S 1542, the DRUG Act; S 1967 the Patients Before Middlemen Act; S 2243, the Palliative Care and Hospice Education and Training Act; S 2483, the Strengthening Consumer Protections and Medical Debt Transparency Act; S 2973, the Modernizing and Ensuring PBM Accountability Act; S 3167, Multiple Employer Welfare Arrangement (MEWA) Act; Legislation to protect insurance purchasers interacting with insurance brokers; Implementation of the No Surprises Act; Federal rulemaking related to Short-term Limited Duration Insurance (STLDI) plans; Insurance appeals and denials; Federal rulemaking related to Association Health Plans; Consumer protections related to consumers who will lose insurance due to the end of certain federal Medicaid maintenance-of-effort requirements; FDA draft guidance related to dose optimization studies in clinical trials

Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including Gabriella Miller Kids First Research Act 2.0 (HR 3391, S 1624); Accelerating Kids Access to Care Act(HR 3089, S 1544); Innovation in Pediatric Drugs Act of 2023 (HR 6664)

Client expense: $56,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Childhood Cancer STAR Act (P.L. 115-180) Childhood Cancer STAR Reauthorization Act (P.L. 117-350) Fiscal Year 2024, Labor, Health, and Human Services Appropriation Fiscal Year 2024 Defense Appropriations H.R. 3391/S. 1624, the Gabriella Miller Kids First Research Act 2.0 H.R. 3663, the PREVENT HPV Cancers Act H.R. 4363/S. 2213, the Comprehensive Cancer Survivorship Act H.R. 4758/S. 2372, the Accelerating Kids' Access to Care Act

Client expense: Not reported · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Office of Science & Technology Policy (OSTP), SENATE

S 652/HR 2630: Safe Step Act- implementing safe guards around step therapy (fail first) programs in ERISA regulated plan S 1375/HR 830: HELP Copays Act- copay accumulator programs Addressing Pharmacy Benefit Managers S 127: Pharmacy Benefit Manager Transparency Act of 2023- prevents unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs S 79: Interagency Patent Coordination and Improvement Act of 2023- establishes an interagency taskforce between the United States Patent and Trademark Office and the FDA S 2243: Palliative Care and Hospice Education and Training Act (PCHETA)- promote education and research in palliative care and hospice Palliative care S 2213: Comprehensive Cancer Survivorship Act- cancer survivorship S 2039: Cancer Drug Parity Act of 2023- oral parity for cancer drugs HR 3633: PREVENT HPV Cancers Act of 2023 S 1624/HR 3391: Gabriella Miller Kids First Research Act 2.0- pediatric cancer research Addressing healthcare workforce shortages Increasing diversity in clinical trials Mitigating drug shortages and increasing supply chain resiliency and future pandemic preparedness, including bolstering the strategic national stockpile S 1961: Pharmaceutical Supply Chain Risk Assessment Act of 2023- require an interagency risk assessment of the pharmaceutical supply chain to identify and mitigate health and national security risks HR 3810: Drug Origin Transparency Act of 2023 - Require drug manufacturers to report to the Food and Drug Administration (FDA) quarterly the supplier's location and drug ingredients HR 3793: Ensuring Access to Lifesaving Drugs Act of 2023 - require manufacturers of life-saving drugs to submit data and information to assess the stability of the drugs and determine their longest supported expiration date, and for other purposes. HR 3008: Drug Shortage Prevention Act of 2023 - Require manufacturers to provide initial notification to the FDA no more than 48 hours after a sustained increase in demand for a drug S 2364: MAPS ACT - A bill to map the United States pharmaceutical supply chain S 2510: RAPID Reserve Act - establish reserves of both Active Pharmaceutical Ingredients (APIs) and finished drug products to be held as vendor-managed inventory and used when needed to prevent supply disruptions HR 5526: Seniors' Access to Critical Medications Act of 2023 - make permanent a waiver issued by the Centers for Medicare and Medicaid Services (CMS) that allowed for Medicare patients to receive critical medications by mail or allow for caregivers and family members to obtain medications for them. HR 6301: Cancer Drug Parity Act of 2023 - To amend the Employee Retirement Income Security Act of 1974 to require a group health plan (or health insurance coverage offered in connection with such a plan) to provide for cost-sharing for oral anticancer drugs on terms no less favorable than the cost-sharing provided for anticancer medications administered by a health care provider. HR 6963: To direct the Secretary of Health and Human Services to enter into agreements with drug manufacturers to establish reserve supplies of covered pediatric cancer drugs, and for other purposes - establish reserve supplies of covered pediatric cancer drugs, and for other purposes.

HR 3991 / S 1624, the Gabriella Miller Kids First Act; Implementation of the Childhood Cancer STAR Act (enacted in 2022);

Client expense: $100,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE

HR 3991 / S 1624, the Gabriella Miller Kids First Act; HR 3503 / S 1701, The NIH Clinical Trial Diversity Act; HR 6301 / S. 2039, The Cancer Drug Parity Act; HR 824, the Telehealth Benefit Expansion for Workers Act; HR 2868, the Association Health Plans; HR 2813, Self-Insurance Protection Act; HR 3799, CHOICE Arrangement Act; HR 4363 / S 2213, Comprehensive Cancer Survivorship Act; HR 2630 / S 652, the Safe Step Act; HR 7383 / S 1214, the RARE Act; S 2243, the Palliative Care and Hospice Education and Training Act; S 3167, Multiple Employer Welfare Arrangement (MEWA) Act; HR 1692 / S 8, the Health Care Affordability Act; HR 3800, the Chronic Disease Flexible Coverage Act; HR 5688 the Bipartisan HSA Improvement Act; HR 5687, the HSA Modernization Act; HR 5609, the Advancing Health Savings Act; HR 1773, the Consumer Protection for Medical Debt Collections Act; S 2483, the Strengthening Consumer Protections and Medical Debt Transparency Act; HR 6003 / S 3103, the Medical Debt Relief Act; HR 7384, the Creating Hope Reauthorization Act; HR 6664, the Innovation in Pediatric Drugs Act; HR 6963, the Pediatric Cancer Drug Supply Chain Act; HR 3433 / S 2897, the Give Kids a Chance Act; S 127, the Pharmacy Benefit Manager Transparency Act; S 113, the Prescription Pricing for the People Act; HR 2880, the Protecting Patients Against PBM Abuses Act; S 1967 the Patients Before Middlemen Act; S 2973, the Modernizing and Ensuring PBM Accountability Act; S 1339, the Pharmacy Benefit Manager Reform Act; S 1542, the DRUG Act; Implementation of the FY23 omnibus, specifically provisions related to increasing access to clinical trials; Implementation of the No Surprises Act; Federal rulemaking related to Short-term Limited Duration Insurance (STLDI) plans; Insurance appeals and denials; Federal rulemaking related to Association Health Plans; Consumer protections related to consumers who will lose insurance due to the end of certain federal Medicaid maintenance-of-effort requirements; Legislation to increase federal investment in Consumer Assistance Programs; FDA draft guidance related to dose optimization studies in clinical trials

S 652/HR 2630: Safe Step Act- implementing safe guards around step therapy (fail first) programs in ERISA regulated plan S 1375/HR 830: HELP Copays Act- copay accumulator programs Addressing Pharmacy Benefit Managers S 127: Pharmacy Benefit Manager Transparency Act of 2023- prevents unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs S 79: Interagency Patent Coordination and Improvement Act of 2023- establishes an interagency taskforce between the United States Patent and Trademark Office and the FDA S 2243: Palliative Care and Hospice Education and Training Act (PCHETA)- promote education and research in palliative care and hospice Palliative care S 2213: Comprehensive Cancer Survivorship Act- cancer survivorship S 2039: Cancer Drug Parity Act of 2023- oral parity for cancer drugs HR 3633: PREVENT HPV Cancers Act of 2023 S 1624/HR 3391: Gabriella Miller Kids First Research Act 2.0- pediatric cancer research Addressing healthcare workforce shortages Increasing diversity in clinical trials Mitigating drug shortages and increasing supply chain resiliency and future pandemic preparedness, including bolstering the strategic national stockpile S 1961: Pharmaceutical Supply Chain Risk Assessment Act of 2023- require an interagency risk assessment of the pharmaceutical supply chain to identify and mitigate health and national security risks HR 3810: Drug Origin Transparency Act of 2023 - Require drug manufacturers to report to the Food and Drug Administration (FDA) quarterly the supplier's location and drug ingredients HR 3793: Ensuring Access to Lifesaving Drugs Act of 2023 - require manufacturers of life-saving drugs to submit data and information to assess the stability of the drugs and determine their longest supported expiration date, and for other purposes. HR 3008: Drug Shortage Prevention Act of 2023 - Require manufacturers to provide initial notification to the FDA no more than 48 hours after a sustained increase in demand for a drug S 2364: MAPS ACT - A bill to map the United States pharmaceutical supply chain S 2510: RAPID Reserve Act - establish reserves of both Active Pharmaceutical Ingredients (APIs) and finished drug products to be held as vendor-managed inventory and used when needed to prevent supply disruptions HR 5526: Seniors' Access to Critical Medications Act of 2023 - make permanent a waiver issued by the Centers for Medicare and Medicaid Services (CMS) that allowed for Medicare patients to receive critical medications by mail or allow for caregivers and family members to obtain medications for them. HR 6301: Cancer Drug Parity Act of 2023 - To amend the Employee Retirement Income Security Act of 1974 to require a group health plan (or health insurance coverage offered in connection with such a plan) to provide for cost-sharing for oral anticancer drugs on terms no less favorable than the cost-sharing provided for anticancer medications administered by a health care provider. HR 6963: To direct the Secretary of Health and Human Services to enter into agreements with drug manufacturers to establish reserve supplies of covered pediatric cancer drugs, and for other purposes - establish reserve supplies of covered pediatric cancer drugs, and for other purposes.

Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including Gabriella Miller Kids First Research Act 2.0 (HR 3391, S 1624); Accelerating Kids Access to Care Act(HR 3089, S 1544); Innovation in Pediatric Drugs Act of 2023 (HR 6664)

Client expense: $169,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Childhood Cancer STAR Act (P.L. 115-180) Childhood Cancer STAR Reauthorization Act (P.L. 117-350) Fiscal Year 2024, Labor, Health, and Human Services Appropriation Fiscal Year 2024 Defense Appropriations H.R. 3391/S. 1624, the Gabriella Miller Kids First Research Act 2.0 H.R. 3663, the PREVENT HPV Cancers Act H.R. 4363/S. 2213, the Comprehensive Cancer Survivorship Act H.R. 4758/S. 2372, the Accelerating Kids' Access to Care Act

Client expense: Not reported · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Office of Science & Technology Policy (OSTP), SENATE

Childhood Cancer STAR Act (P.L. 115-180) Childhood Cancer STAR Reauthorization Act (P.L. 117-350) Fiscal Year 2024, Labor, Health, and Human Services Appropriation Fiscal Year 2024 Defense Appropriations H.R. 3391/S. 1624, the Gabriella Miller Kids First Research Act 2.0 H.R. 3663, the PREVENT HPV Cancers Act H.R. 4363/S. 2213, the Comprehensive Cancer Survivorship Act H.R. 4758/S. 2372, the Accelerating Kids' Access to Care Act

Client expense: Not reported · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Office of Science & Technology Policy (OSTP), SENATE

Childhood Cancer STAR Act (P.L. 115-180) Childhood Cancer STAR Reauthorization Act (P.L. 117-350) Fiscal Year 2024, Labor, Health, and Human Services Appropriation Fiscal Year 2024 Defense Appropriations H.R. 3391/S. 1624, the Gabriella Miller Kids First Research Act 2.0 H.R. 3663, the PREVENT HPV Cancers Act H.R. 4363/S. 2213, the Comprehensive Cancer Survivorship Act H.R. 4758/S. 2372, the Accelerating Kids' Access to Care Act

Client expense: Not reported · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Office of Science & Technology Policy (OSTP), SENATE

HR 711, the Throw Away Junk Plans Act; HR 3991 / S 1624, the Gabriella Miller Kids First Act; HR 3503 / S 1701, The NIH Clinical Trial Diversity Act; S. 2039, The Cancer Drug Parity Act; HR 824, the Telehealth Benefit Expansion Act; HR 2868, the Association Health Plans; HR 2813, Self-Insurance Protection Act; HR 3799, CHOICE Arrangement Act; HR 4363 / S 2213, Comprehensive Cancer Survivorship Act; S 652, the Safe Step Act; S 1214, the RARE Act; S 2243, the Palliative Care and Hospice Education and Training Act; draft legislation regarding Health Care Sharing Ministry transparency; Implementation of the FY23 omnibus, specifically provisions related to increasing access to clinical trials; Implementation of the No Surprises Act; Federal rulemaking related to Short-term Limited Duration Insurance (STLDI) plans; Insurance appeals and denials; Federal rulemaking related to Association Health Plans; Consumer protections related to consumers who will lose insurance due to the end of certain federal Medicaid maintenance-of-effort requirements; Legislation to increase federal investment in Consumer Assistance Programs; FDA draft guidance related to dose optimization studies in clinical trials

Client expense: $440,000 · Firm income: Not reported

HR 3991 / S 1624, the Gabriella Miller Kids First Act; Implementation of the Childhood Cancer STAR Act (enacted in 2022);

Client expense: $440,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE

Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including Gabriella Miller Kids First Research Act 2.0 (HR 3391, S 1624); Accelerating Kids Access to Care Act(HR 3089, S 1544); Innovation in Pediatric Drugs Act of 2023 (HR 6664)

Client expense: $77,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S 652/HR 2630: Safe Step Act- implementing safe guards around step therapy (fail first) programs in ERISA regulated plan S 1375/HR 830: HELP Copays Act- copay accumulator programs Addressing Pharmacy Benefit Managers S 127: Pharmacy Benefit Manager Transparency Act of 2023- prevents unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs S 79: Interagency Patent Coordination and Improvement Act of 2023- establishes an interagency taskforce between the United States Patent and Trademark Office and the FDA S 2243: Palliative Care and Hospice Education and Training Act (PCHETA)- promote education and research in palliative care and hospice Palliative care S 2213: Comprehensive Cancer Survivorship Act- cancer survivorship S 2039: Cancer Drug Parity Act of 2023- oral parity for cancer drugs HR 3633: PREVENT HPV Cancers Act of 2023 S 1624/HR 3391: Gabriella Miller Kids First Research Act 2.0- pediatric cancer research Addressing healthcare workforce shortages Increasing diversity in clinical trials Mitigating drug shortages and increasing supply chain resiliency and future pandemic preparedness, including bolstering the strategic national stockpile S 1961: Pharmaceutical Supply Chain Risk Assessment Act of 2023- require an interagency risk assessment of the pharmaceutical supply chain to identify and mitigate health and national security risks HR 3810: Drug Origin Transparency Act of 2023 - Require drug manufacturers to report to the Food and Drug Administration (FDA) quarterly the supplier's location and drug ingredients HR 3793: Ensuring Access to Lifesaving Drugs Act of 2023 - require manufacturers of life-saving drugs to submit data and information to assess the stability of the drugs and determine their longest supported expiration date, and for other purposes. HR 3008: Drug Shortage Prevention Act of 2023 - Require manufacturers to provide initial notification to the FDA no more than 48 hours after a sustained increase in demand for a drug S 2364: MAPS ACT - A bill to map the United States pharmaceutical supply chain S 2510: RAPID Reserve Act - establish reserves of both Active Pharmaceutical Ingredients (APIs) and finished drug products to be held as vendor-managed inventory and used when needed to prevent supply disruptions HR 5526: Seniors' Access to Critical Medications Act of 2023 - make permanent a waiver issued by the Centers for Medicare and Medicaid Services (CMS) that allowed for Medicare patients to receive critical medications by mail or allow for caregivers and family members to obtain medications for them. HR 6301: Cancer Drug Parity Act of 2023 - To amend the Employee Retirement Income Security Act of 1974 to require a group health plan (or health insurance coverage offered in connection with such a plan) to provide for cost-sharing for oral anticancer drugs on terms no less favorable than the cost-sharing provided for anticancer medications administered by a health care provider. HR 6963: To direct the Secretary of Health and Human Services to enter into agreements with drug manufacturers to establish reserve supplies of covered pediatric cancer drugs, and for other purposes - establish reserve supplies of covered pediatric cancer drugs, and for other purposes PN 649: Monica M. Bertagnolli, Department of Health and Human Services - Nomination of Monica Bertagnolli for the Director of the National Institutes of Health

HR 35, the Close the Medigap Act; HR 711, the Throw Away Junk Plans Act; HR 3991 / S 1624, the Gabriella Miller Kids First Act; HR 3503 / S 1701, The NIH Clinical Trial Diversity Act; S. 2039, The Cancer Drug Parity Act; HR 824, the Telehealth Benefit Expansion Act; HR 2868, the Association Health Plans; HR 2813, Self-Insurance Protection Act; HR 3799, CHOICE Arrangement Act; HR 4363 / S 2213, Comprehensive Cancer Survivorship Act; S 652, the Safe Step Act; S 1214, the RARE Act; S 2243, the Palliative Care and Hospice Education and Training Act; draft legislation regarding Health Care Sharing Ministry transparency; Implementation of the FY23 omnibus, specifically provisions related to increasing access to clinical trials; Implementation of the No Surprises Act; Federal rulemaking related to Short-term Limited Duration Insurance (STLDI) plans; Insurance appeals and denials; Federal rulemaking related to Association Health Plans; Consumer protections related to consumers who will lose insurance due to the end of certain federal Medicaid maintenance-of-effort requirements; Legislation to increase federal investment in Consumer Assistance Programs; FDA draft guidance related to dose optimization studies in clinical trials

Client expense: $150,000 · Firm income: Not reported

HR 3991 / S 1624, the Gabriella Miller Kids First Act; Implementation of the Childhood Cancer STAR Act (enacted in 2022);

Client expense: $150,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE

Childhood Cancer STAR Act (P.L. 115-180) Childhood Cancer STAR Reauthorization Act (P.L. 117-350) Fiscal Year 2024, Labor, Health, and Human Services Appropriation Fiscal Year 2024 Defense Appropriations H.R. 3391/S. 1624, the Gabriella Miller Kids First Research Act 2.0 H.R. 3663, the PREVENT HPV Cancers Act H.R. 4363/S. 2213, the Comprehensive Cancer Survivorship Act H.R. 4758/S. 2372, the Accelerating Kids' Access to Care Act

Client expense: Not reported · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Office of Science & Technology Policy (OSTP), SENATE

S.895/H.R. 902, Ellies Law: Funding for comprehensive research at the National Institute of Neurological Disorders and Stroke on unruptured intracranial aneurysms. S.1026/H.R. 2390, Gun Violence Prevention Research Act: To authorize the appropriation of funds to the Centers for Disease Control and Prevention for conducting or supporting research on firearms safety or gun violence prevention. S. 1624/H.R. 3391, Gabriella Miller Kids First Research Act 2.0: To require certain civil penalties to be transferred to a fund through which amounts are made available for the Gabriella Miller Kids First Pediatric Research Program at the National Institutes of Health. No Bill: Funding for the U.S. Centers for Disease Control and Prevention, the National Institutes of Health, and the National Institute of Justice to conduct public health research into firearm morbidity and mortality prevention. No Bill: Funding for MISSION ZERO military/civilian trauma preparedness program. No Bill: Funding for the Pediatric Subspecialty Loan Repayment Program. No Bill: Increased funding for the National Institutes of Health for biomedical research.

Client expense: $45,000 · Firm income: Not reported

S.895/H.R. 902, Ellies Law: Funding for comprehensive research at the National Institute of Neurological Disorders and Stroke on unruptured intracranial aneurysms. S.1026/H.R. 2390, Gun Violence Prevention Research Act: To authorize the appropriation of funds to the Centers for Disease Control and Prevention for conducting or supporting research on firearms safety or gun violence prevention. S. 1624/H.R. 3391, Gabriella Miller Kids First Research Act 2.0: To require certain civil penalties to be transferred to a fund through which amounts are made available for the Gabriella Miller Kids First Pediatric Research Program at the National Institutes of Health. No Bill: Funding for the U.S. Centers for Disease Control and Prevention, the National Institutes of Health, and the National Institute of Justice to conduct public health research into firearm morbidity and mortality prevention. No Bill: Funding for MISSION ZERO military/civilian trauma preparedness program. No Bill: Funding for the Pediatric Subspecialty Loan Repayment Program. No Bill: Increased funding for the National Institutes of Health for biomedical research.

Client expense: $45,000 · Firm income: Not reported

Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including Gabriella Miller Kids First Research Act 2.0 (HR 3391, S 1624); Accelerating Kids Access to Care Act(HR 3089, S 1544)

Client expense: $75,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S 652/HR 2630: Safe Step Act- implementing safe guards around step therapy (fail first) programs in ERISA regulated plan S 1375/HR 830: HELP Copays Act- copay accumulator programs Addressing Pharmacy Benefit Managers S 127: Pharmacy Benefit Manager Transparency Act of 2023- prevents unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs S 79: Interagency Patent Coordination and Improvement Act of 2023- establishes an interagency taskforce between the United States Patent and Trademark Office and the FDA S 2243: Palliative Care and Hospice Education and Training Act (PCHETA)- promote education and research in palliative care and hospice Palliative care S 2213: Comprehensive Cancer Survivorship Act- cancer survivorship S 2039: Cancer Drug Parity Act of 2023- oral parity for cancer drugs HR 3633: PREVENT HPV Cancers Act of 2023 S 1624/HR 3391: Gabriella Miller Kids First Research Act 2.0- pediatric cancer research Addressing healthcare workforce shortages Increasing diversity in clinical trials Mitigating drug shortages and increasing supply chain resiliency and future pandemic preparedness, including bolstering the strategic national stockpile S 1961: Pharmaceutical Supply Chain Risk Assessment Act of 2023- require an interagency risk assessment of the pharmaceutical supply chain to identify and mitigate health and national security risks HR 3810: Drug Origin Transparency Act of 2023 - Require drug manufacturers to report to the Food and Drug Administration (FDA) quarterly the supplier's location and drug ingredients HR 3793: Ensuring Access to Lifesaving Drugs Act of 2023 - require manufacturers of life-saving drugs to submit data and information to assess the stability of the drugs and determine their longest supported expiration date, and for other purposes. HR 3008: Drug Shortage Prevention Act of 2023 - Require manufacturers to provide initial notification to the FDA no more than 48 hours after a sustained increase in demand for a drug S 2364: MAPS ACT - A bill to map the United States pharmaceutical supply chain S 2510: RAPID Reserve Act - establish reserves of both Active Pharmaceutical Ingredients (APIs) and finished drug products to be held as vendor-managed inventory and used when needed to prevent supply disruptions

H.R. 824 - Telehealth Benefit Expansion for Workers Act of 2023 H.R. 1202 / S. 704 - Resident Education Deferred Interest (REDI) Act H.R. 2389 - Resident Physician Shortage Reduction Act of 2023 H.R. 2400 / S. 1165 - Reentry Act of 2023 H.R. 3226 - Prematurity Research Expansion and Education for Mothers who deliver Infants Early (PREEMIE) Reauthorization Act of 2023 H.R. 3305 / S. 1606 - Black Maternal Health Momnibus Act H.R. 3312 / S. 1602 - Moms Matter Act H.R. 3331 / S. 754 - Improving Mental Health and Wellness in School Act H.R. 3391 / S. 1624 - Gabriella Miller Kids First Research Act 2.0 H.R. 3432 - Telemental Health Care Access Act of 2023 H.R. 3805 - KIDS Health Act of 2023 H.R. 3813 - CDC Leadership Accountability Act of 2023 H.R. 3821 - Firefighter Cancer Registry Reauthorization Act of 2023 H.R. 3836 - Medicaid Primary Care Improvement Act H.R. 3838 - Preventing Maternal Deaths Reauthorization Act of 2023 H.R. 3841 - To amend title III of the Public Health Service Act to reauthorize the program of payments to children's hospitals that operate graduate medical education programs H.R. 3843 - Action for Dental Health Act of 2023 H.R. 3884 - Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023 H.R. 3887 - Childrens Hospital GME Support Reauthorization Act of 2023 H.R. 4189 / S. 2016 - CONNECT for Health Act of 2023 H.R. 4331 - Strengthening Medicaid for Serious Mental Illness Act H.R. 4381 - Public Health Emergency Congressional Review Act H.R. 4420 - Preparedness and Response Reauthorization Act H.R. 4421 - Preparing for All Hazards and Pathogens Reauthorization Act H.R. 4529 - Public Health Guidance Transparency and Accountability Act of 2023 H.R. 4531 / S. 2433 - SUPPORT for Patients and Communities Reauthorization Act H.R. 4830 / S. 2444 - ATTAIN Mental Health Act H.R. 4837 - Building a Health Care Workforce for the Future Act H.R. 4851 - 988 Implementation Assistance Act H.R. 4884 / S. 2476 - Mental Health for Latinos Act H.R. 4892 - Medicaid Bump Act H.R. 4911 - Supporting the Health and Safety of Law Enforcement Act H.R. 4918 - Solutions Not Stigmas Act of 2023 H.R. 4933 / S. 462 - Mental Health Professionals Workforce Shortage Loan Repayment Act H.R. 4941 - PATH Act H.R. 4942 / S. 665 - Conrad State 30 and Physician Access Reauthorization Act H.R. 4950 / S. 2481 - IMPROVE Addictions Care Act H.R. 4968 - GOLD CARD Act of 2023 H.R. 5010 - Recognizing Gun Violence as a Public Health Emergency Act H.R. 5116 / S. 2688 - Behavioral Health Information Technology (BHIT) Coordination Act H.R. 5128 / S. 2137 - Preserving Access to Home Health Act of 2023 H.R. 5163 - Telehealth Response for E-prescribing Addiction Therapy Services Act H.R. 5312 - Supporting Healthy Mothers and Infants Act of 2023 H.R. 5414 / S. 1346 - Improving Mental Health Access for the Emergency Department Act of 2023 H.R. 5568 - CARE for Moms Act H.R. 5804 - Mental Health Infrastructure Improvement Act of 2023 H.R. 5819 / S. 1378 - COMPLETE Care Act H.R. 5976 / S. 3060 - Youth Mental Health Research Act S. 1291 - Protecting Kids on Social Media Act S. 2308 - Community Health Care Reauthorization Act S. 2840 - Bipartisan Primary Care and Health Workforce Expansion Act S. 2556 - Improving CARE for Youth Act S. 2511 - ADAPT Act S. 2733 - PEER Support Act S. 2966 - TEAMS Act

HR 3991 / S 1624, the Gabriella Miller Kids First Act; Implementation of the Childhood Cancer STAR Act (enacted in 2022);

Client expense: $480,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE

HR 35, the Close the Medigap Act; HR 711, the Throw Away Junk Plans Act; HR 3991 / S 1624, the Gabriella Miller Kids First Act; HR 3503 / S 1701, The NIH Clinical Trial Diversity Act; S. 2039, The Cancer Drug Parity Act; HR 824, the Telehealth Benefit Expansion Act; HR 2868, the Association Health Plans; HR 2813, Self-Insurance Protection Act; HR 3799, CHOICE Arrangement Act; HR 4363 / S 2213, Comprehensive Cancer Survivorship Act; S 652, the Safe Step Act; S 1214, the RARE Act; The DIVERSE Trails Act (yet to be introduced); The DEPICT Act (yet to be introduced); Implementation of the FY23 omnibus, specifically provisions related to increasing access to clinical trials; Implementation of the No Surprises Act; Federal rulemaking related to Short-term Limited Duration Insurance (STLDI) plans; FDA regulatory action related to the safety of infusion bags of varying sizes; Insurance appeals and denials; Federal rulemaking related to Association Health Plans; Consumer protections related to consumers who will lose insurance due to the end of certain federal Medicaid maintenance-of-effort requirements;

Client expense: $480,000 · Firm income: Not reported

S.895/H.R. 902, Ellies Law: Funding for comprehensive research at the National Institute of Neurological Disorders and Stroke on unruptured intracranial aneurysms. S.1026/H.R. 2390, Gun Violence Prevention Research Act: To authorize the appropriation of funds to the Centers for Disease Control and Prevention for conducting or supporting research on firearms safety or gun violence prevention. S. 1624/H.R. 3391, Gabriella Miller Kids First Research Act 2.0: To require certain civil penalties to be transferred to a fund through which amounts are made available for the Gabriella Miller Kids First Pediatric Research Program at the National Institutes of Health. No Bill: Funding for Neglected Surgical Conditions within the State, Foreign Operations, and Related Programs (SFOPS) Appropriations Report for Fiscal Year (FY) 2024. No Bill: Funding for the U.S. Centers for Disease Control and Prevention, the National Institutes of Health, and National Institute of Justice to conduct public health research into firearm morbidity and mortality prevention. No Bill: Funding for MISSION ZERO military/civilian trauma preparedness program. No Bill: Funding for the Pediatric Subspecialty Loan Repayment Program. No Bill: Increased funding for the National Institutes of Health for biomedical research. No Bill: Funding for the Pediatric Device Consortia Grant Program at the Office of Orphan Products Development at the Food and Drug Administration.

Client expense: $35,000 · Firm income: Not reported

S.895/H.R. 902, Ellies Law: Funding for comprehensive research at the National Institute of Neurological Disorders and Stroke on unruptured intracranial aneurysms. S.1026/H.R. 2390, Gun Violence Prevention Research Act: To authorize the appropriation of funds to the Centers for Disease Control and Prevention for conducting or supporting research on firearms safety or gun violence prevention. S. 1624/H.R. 3391, Gabriella Miller Kids First Research Act 2.0: To require certain civil penalties to be transferred to a fund through which amounts are made available for the Gabriella Miller Kids First Pediatric Research Program at the National Institutes of Health. No Bill: Funding for Neglected Surgical Conditions within the State, Foreign Operations, and Related Programs (SFOPS) Appropriations Report for Fiscal Year (FY) 2024 No Bill: Funding for the U.S. Centers for Disease Control and Prevention, the National Institutes of Health, and National Institute of Justice to conduct public health research into firearm morbidity and mortality prevention. No Bill: Funding for MISSION ZERO military/civilian trauma preparedness program No Bill: Funding for the Pediatric Subspecialty Loan Repayment Program No Bill: Increased funding for the National Institutes of Health for biomedical research. No Bill: Funding for the Pediatric Device Consortia Grant Program at the Office of Orphan Products Development at the Food and Drug Administration.

Client expense: $35,000 · Firm income: Not reported

Childhood Cancer STAR Act (P.L. 115-180) Childhood Cancer STAR Reauthorization Act (P.L. 117-350) Fiscal Year 2024 Labor, Health, and Human Services Appropriations Fiscal Year 2024 Defense Appropriations H.R. 3391/S. 1624, the Gabriella Miller Kids First Research Act 2.0 H.R. 3663, the PREVENT HPV Cancers Act

Client expense: $10,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Office of Science & Technology Policy (OSTP), SENATE

Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including Gabriella Miller Kids First Research Act 2.0 (HR 3391, S 1624); Accelerating Kids Access to Care Act(HR 3089, S 1544)

Client expense: $30,156 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S 652/HR 2630: Safe Step Act- implementing safe guards around step therapy (fail first) programs in ERISA regulated plans HR 830/S 1375: HELP Copays Act- copay accumulator programs S 127: Pharmacy Benefit Manager Transparency Act of 2023- prevents unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs S 79: Interagency Patent Coordination and Improvement Act of 2023- establishes an interagency taskforce between the United States Patent and Trademark Office and the FDA S 2243: Palliative Care and Hospice Education and Training Act (PCHETA)- promote education and research in palliative care and hospice Palliative care S 2213: Comprehensive Cancer Survivorship Act- cancer survivorship S 2039: Cancer Drug Parity Act of 2023- oral parity for cancer drugs HR 3633: PREVENT HPV Cancers Act of 2023 S 1624/HR 3391: Gabriella Miller Kids First Research Act 2.0- pediatric cancer research Addressing healthcare workforce shortages Increasing diversity in clinical trials S 1961: Pharmaceutical Supply Chain Risk Assessment Act of 2023- require an interagency risk assessment of the pharmaceutical supply chain to identify and mitigate health and national security risks Mitigating drug shortages and increasing supply chain resiliency and future pandemic preparedness, including bolstering the strategic national stockpile Regulating Laboratory Developed Tests (LDTs) and in vitro diagnostic tests (IVDs)

Client expense: $460,000 · Firm income: Not reported